Pfizer’s Prevnar 13 Is Approved For Older Children As Use In Adults Lags
Executive Summary
FDA approved use of the pneumococcal vaccine in children and adolescents aged six to 17 years; uptake in adults 50 and older has been impacted by the delay in getting an ACIP vote on treatment, which is expected later this year.
You may also be interested in...
Prevnar 13 Recommendation For Medicare Population May Be Short Lived
CDC advisory committee support for Pfizer pneumococcal vaccine in adults 65 and older comes with caveat that recommendation will be re-examined, and possibly revised, in 2018 due to effects of herd immunity.
Vaccines Chess Game Continues With Baxter Sale To Pfizer
Pfizer, which saw 13% growth in its global vaccines business during the second quarter, pays $635 million to buy a pair of vaccines from Baxter. The meningitis and encephalitis vaccines, sold mainly in Europe, are expected to generate combined sales of about $300 million this year.
No Near-Term Separations For Pfizer, But Business Model Will “Evolve”
Beyond the sale of its nutritionals business and spin-out of animal health into Zoetis, no additional separations are planned for Pfizer in the near-term. But CEO Ian Read discussed how he sees the company’s Established Products and Emerging Markets businesses evolving over the long-term, including the potential for an eventual breakout, during a year-end financial call Jan. 29.